In the last 12 months, insiders at RESMED INC ($RMD) filed 267 transactions with the SEC: 0 open-market purchases totaling $0 and 99 sales totaling $97,124,333. Net insider sentiment: net selling.
RESMED INC operates in the Surgical & medical instruments & apparatus industry (Industrial Applications and Services sector).
Most Active Insiders
- Farrell Michael J. (Chief Executive Officer) — 60 transactions totaling $59,870,161
- FARRELL PETER C (Director) — 29 transactions totaling $16,093,660
- Sandercock Brett (Chief Financial Officer) — 42 transactions totaling $14,160,256
- Farrell Michael J. (Chairman and CEO) — 23 transactions totaling $12,825,924
- Ghoshal Kaushik (Chief Commercial Officer, SaaS) — 32 transactions totaling $11,804,244
View all SEC Filings for RESMED INC (RMD).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $224.31 | 83,495.0000 | 190,814,000 | 1.18% | 0.00% |
| April 1, 2026 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $225.00 | 60,773.0000 | 190,814,000 | 3.19% | 0.00% |
| March 9, 2026 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock | 4991 | $146.34 | 473,304.0000 | 190,814,000 | 1.07% | 0.00% |
| March 9, 2026 | Farrell Michael J. | Chairman and CEO | S | ResMed Common Stock | 4991 | $251.03 | 468,313.0000 | 190,814,000 | 1.05% | 0.00% |
| March 9, 2026 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock Options | 4991 | $0.00 | 39,930.0000 | 190,814,000 | 11.11% | 0.00% |
| March 4, 2026 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $260.22 | 62,773.0000 | 190,814,000 | 3.09% | 0.00% |
| March 2, 2026 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $254.30 | 84,495.0000 | 190,814,000 | 1.17% | 0.00% |
| Feb. 9, 2026 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock | 4991 | $146.34 | 473,304.0000 | 190,814,000 | 1.07% | 0.00% |
| Feb. 9, 2026 | Farrell Michael J. | Chairman and CEO | S | ResMed Common Stock | 4991 | $273.78 | 468,313.0000 | 190,814,000 | 1.05% | 0.00% |
| Feb. 9, 2026 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock Options | 4991 | $0.00 | 44,921.0000 | 190,814,000 | 10.00% | 0.00% |
| Feb. 4, 2026 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 50 | $260.00 | 9,691.0000 | 190,814,000 | 0.51% | 0.00% |
| Feb. 4, 2026 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $251.31 | 64,773.0000 | 190,814,000 | 3.00% | 0.00% |
| Feb. 2, 2026 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $257.03 | 85,495.0000 | 190,814,000 | 1.16% | 0.00% |
| Jan. 7, 2026 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $248.83 | 66,773.0000 | 190,814,000 | 2.91% | 0.00% |
| Jan. 7, 2026 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock Options | 4991 | $0.00 | 49,912.0000 | 190,814,000 | 9.09% | 0.00% |
| Jan. 7, 2026 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock | 4991 | $146.34 | 473,304.0000 | 190,814,000 | 1.07% | 0.00% |
| Jan. 7, 2026 | Farrell Michael J. | Chairman and CEO | S | ResMed Common Stock | 4991 | $248.46 | 468,313.0000 | 190,814,000 | 1.05% | 0.00% |
| Jan. 2, 2026 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $241.75 | 86,495.0000 | 190,814,000 | 1.14% | 0.00% |
| Jan. 2, 2026 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 50 | $241.75 | 9,741.0000 | 190,814,000 | 0.51% | 0.00% |
| Dec. 8, 2025 | Farrell Michael J. | Chairman and CEO | S | ResMed Common Stock | 4991 | $251.41 | 468,313.0000 | 190,390,000 | 1.05% | 0.00% |
| Dec. 8, 2025 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock Options | 4991 | $0.00 | 54,903.0000 | 190,390,000 | 8.33% | 0.00% |
| Dec. 8, 2025 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock | 4991 | $146.34 | 473,304.0000 | 190,390,000 | 1.07% | 0.00% |
| Dec. 3, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $251.47 | 68,773.0000 | 190,390,000 | 2.83% | 0.00% |
| Dec. 1, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 50 | $244.16 | 9,791.0000 | 190,390,000 | 0.51% | 0.00% |
| Dec. 1, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $244.16 | 87,495.0000 | 190,390,000 | 1.13% | 0.00% |
| Nov. 24, 2025 | Farrell Michael J. | Chairman and CEO | A | ResMed Common Stock Options | 33288 | $250.52 | 33,288.0000 | 190,390,000 | 9999.99% | 0.02% |
| Nov. 24, 2025 | FARRELL PETER C | Director | A | ResMed Common Stock Options | 1331 | $250.52 | 1,331.0000 | 190,390,000 | 9999.99% | 0.00% |
| Nov. 25, 2025 | De Witte Jan | Director | S | ReMed Common Stock | 2055 | $255.00 | 4,261.0000 | 190,390,000 | 32.54% | 0.00% |
| Nov. 24, 2025 | Mowad-Nassar Nicole | Director | A | ResMed Common Stock Options | 1331 | $250.52 | 1,331.0000 | 190,390,000 | 9999.99% | 0.00% |
| Nov. 20, 2025 | Hernandez John | Director | A | ResMed Common Stock | 1073 | $0.00 | 5,118.0000 | 190,390,000 | 26.53% | 0.00% |
| Nov. 20, 2025 | Gill Harjit | Director | A | ResMed Common Stock | 1073 | $0.00 | 10,940.0000 | 190,390,000 | 10.87% | 0.00% |
| Nov. 20, 2025 | Drexler Karen | Director | A | ResMed Common Stock | 1073 | $0.00 | 10,602.0000 | 190,390,000 | 11.26% | 0.00% |
| Nov. 20, 2025 | Burt Carol | Director | A | ResMed Common Stock | 1073 | $0.00 | 2,156.0000 | 190,390,000 | 99.08% | 0.00% |
| Nov. 20, 2025 | TAYLOR RONALD R | Director | A | ResMed Common Stock | 1073 | $0.00 | 24,771.0000 | 190,390,000 | 4.53% | 0.00% |
| Nov. 20, 2025 | Sandercock Brett | Chief Financial Officer | A | ResMed Common Stock | 2710 | $0.00 | 88,495.0000 | 190,390,000 | 3.16% | 0.00% |
| Nov. 20, 2025 | Farrell Michael J. | Chairman and CEO | A | ResMed Common Stock | 13551 | $0.00 | 475,610.0000 | 190,390,000 | 2.93% | 0.01% |
| Nov. 20, 2025 | Farrell Michael J. | Chairman and CEO | F | ResMed Common Stock | 7297 | $0.00 | 468,313.0000 | 190,390,000 | 1.53% | 0.00% |
| Nov. 20, 2025 | DelOrefice Christopher | Director | A | ResMed Common Stock | 1073 | $0.00 | 2,423.0000 | 190,390,000 | 79.48% | 0.00% |
| Nov. 20, 2025 | De Witte Jan | Director | A | ReMed Common Stock | 1073 | $0.00 | 6,316.0000 | 190,390,000 | 20.47% | 0.00% |
| Nov. 20, 2025 | FARRELL PETER C | Director | A | ResMed Common Stock | 536 | $0.00 | 70,773.0000 | 190,390,000 | 0.76% | 0.00% |
| Nov. 20, 2025 | Mowad-Nassar Nicole | Director | A | ResMed Common Stock | 536 | $0.00 | 777.0000 | 190,390,000 | 222.41% | 0.00% |
| Nov. 20, 2025 | Tan Desney | Director | A | ResMed Common Stock | 1073 | $0.00 | 6,002.0000 | 190,390,000 | 21.77% | 0.00% |
| Nov. 20, 2025 | Leong Justin | Chief Product Officer | A | ReMed Common Stock | 1848 | $0.00 | 29,028.0000 | 190,390,000 | 6.80% | 0.00% |
| Nov. 14, 2025 | FARRELL PETER C | Director | M | ResMed Common Stock Options | 11442 | $0.00 | 0.0000 | 190,390,000 | 100.00% | 0.01% |
| Nov. 14, 2025 | FARRELL PETER C | Director | F | ResMed Common Stock | 7314 | $244.46 | 70,238.0000 | 190,390,000 | 9.43% | 0.00% |
| Nov. 14, 2025 | FARRELL PETER C | Director | M | ResMed Common Stock | 11442 | $101.64 | 77,552.0000 | 190,390,000 | 17.31% | 0.01% |
| Nov. 11, 2025 | Gill Harjit | Director | F | ResMed Common Stock | 38 | $250.10 | 9,867.0000 | 190,390,000 | 0.39% | 0.00% |
| Nov. 11, 2025 | De Witte Jan | Director | F | ReMed Common Stock | 76 | $250.10 | 5,242.0000 | 190,390,000 | 1.44% | 0.00% |
| Nov. 11, 2025 | De Witte Jan | Director | S | ReMed Common Stock | 487 | $250.25 | 5,319.0000 | 190,390,000 | 8.39% | 0.00% |
| Nov. 11, 2025 | Farrell Michael J. | Chairman and CEO | F | ResMed Common Stock | 2206 | $250.10 | 462,059.0000 | 190,390,000 | 0.48% | 0.00% |
| Nov. 11, 2025 | Farrell Michael J. | Chairman and CEO | F | ResMed Common Stock | 3459 | $250.10 | 464,265.0000 | 190,390,000 | 0.74% | 0.00% |
| Nov. 11, 2025 | Farrell Michael J. | Chairman and CEO | F | ResMed Common Stock | 2232 | $250.10 | 467,724.0000 | 190,390,000 | 0.47% | 0.00% |
| Nov. 12, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $252.05 | 66,110.0000 | 190,390,000 | 2.94% | 0.00% |
| Nov. 11, 2025 | FARRELL PETER C | Director | F | ResMed Common Stock | 163 | $250.10 | 68,110.0000 | 190,390,000 | 0.24% | 0.00% |
| Nov. 11, 2025 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 501 | $250.10 | 9,841.0000 | 190,390,000 | 4.84% | 0.00% |
| Nov. 11, 2025 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 715 | $250.10 | 10,342.0000 | 190,390,000 | 6.47% | 0.00% |
| Nov. 11, 2025 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 174 | $250.10 | 11,057.0000 | 190,390,000 | 1.55% | 0.00% |
| Nov. 11, 2025 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 135 | $250.10 | 11,231.0000 | 190,390,000 | 1.19% | 0.00% |
| Nov. 7, 2025 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock | 983 | $101.64 | 470,939.0000 | 190,390,000 | 0.21% | 0.00% |
| Nov. 7, 2025 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock Options | 7028 | $0.00 | 0.0000 | 190,390,000 | 100.00% | 0.00% |
| Nov. 7, 2025 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock Options | 983 | $0.00 | 7,028.0000 | 190,390,000 | 12.27% | 0.00% |
| Nov. 7, 2025 | Farrell Michael J. | Chairman and CEO | S | ResMed Common Stock | 8011 | $249.75 | 469,956.0000 | 190,390,000 | 1.68% | 0.00% |
| Nov. 7, 2025 | Farrell Michael J. | Chairman and CEO | M | ResMed Common Stock | 7028 | $101.64 | 477,967.0000 | 190,390,000 | 1.49% | 0.00% |
| Nov. 3, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 2000 | $0.00 | 0.0000 | 190,390,000 | 100.00% | 0.00% |
| Nov. 3, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 2000 | $101.64 | 88,745.0000 | 190,390,000 | 2.31% | 0.00% |
| Nov. 3, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 3000 | $247.54 | 85,745.0000 | 190,390,000 | 3.38% | 0.00% |
| Oct. 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $282.85 | 469,882.0000 | 190,390,000 | 1.68% | 0.00% |
| Oct. 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 477,891.0000 | 190,390,000 | 1.70% | 0.00% |
| Oct. 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 8,011.0000 | 190,390,000 | 49.99% | 0.00% |
| Oct. 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 2000 | $0.00 | 2,000.0000 | 190,390,000 | 50.00% | 0.00% |
| Oct. 1, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 3000 | $274.36 | 86,745.0000 | 190,390,000 | 3.34% | 0.00% |
| Oct. 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 2000 | $101.64 | 89,745.0000 | 190,390,000 | 2.28% | 0.00% |
| Oct. 1, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 100 | $274.36 | 11,327.0000 | 190,390,000 | 0.88% | 0.00% |
| Sept. 8, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $278.14 | 469,882.0000 | 190,311,000 | 1.68% | 0.00% |
| Sept. 8, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 16,020.0000 | 190,311,000 | 33.33% | 0.00% |
| Sept. 8, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 477,891.0000 | 190,311,000 | 1.70% | 0.00% |
| Sept. 2, 2025 | Mowad-Nassar Nicole | Director | A | ResMed Common Stock | 241 | $0.00 | 241.0000 | 190,311,000 | 9999.99% | 0.00% |
| Sept. 2, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 2000 | $101.64 | 90,745.0000 | 190,311,000 | 2.25% | 0.00% |
| Sept. 2, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 3000 | $270.77 | 87,745.0000 | 190,311,000 | 3.31% | 0.00% |
| Sept. 2, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 2000 | $0.00 | 4,000.0000 | 190,311,000 | 33.33% | 0.00% |
| Aug. 15, 2025 | Rider Michael J | Global General Counsel | A | ResMed Common Stock | 2941 | $0.00 | 11,427.0000 | 190,311,000 | 34.66% | 0.00% |
| Aug. 18, 2025 | Hernandez John | Director | M | ResMed Common Stock Options | 2575 | $0.00 | 0.0000 | 190,311,000 | 100.00% | 0.00% |
| Aug. 18, 2025 | Hernandez John | Director | S | ResMed Common Stock | 2575 | $287.10 | 4,045.0000 | 190,311,000 | 38.90% | 0.00% |
| Aug. 18, 2025 | Hernandez John | Director | M | ResMed Common Stock | 2575 | $148.90 | 6,620.0000 | 190,311,000 | 63.66% | 0.00% |
| Aug. 15, 2025 | Farrell Michael J. | Chief Executive Officer | A | ResMed Common Stock | 12289 | $0.00 | 469,882.0000 | 190,311,000 | 2.69% | 0.01% |
| Aug. 15, 2025 | Sandercock Brett | Chief Financial Officer | A | ResMed Common Stock | 5462 | $0.00 | 88,745.0000 | 190,311,000 | 6.56% | 0.00% |
| Aug. 15, 2025 | Leong Justin | Chief Product Officer | A | ReMed Common Stock | 5462 | $0.00 | 27,180.0000 | 190,311,000 | 25.15% | 0.00% |
| Aug. 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 465,602.0000 | 190,311,000 | 1.75% | 0.00% |
| Aug. 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 24,029.0000 | 190,311,000 | 25.00% | 0.00% |
| Aug. 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $279.48 | 457,593.0000 | 190,311,000 | 1.72% | 0.00% |
| Aug. 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 2000 | $101.64 | 86,283.0000 | 190,311,000 | 2.37% | 0.00% |
| Aug. 1, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 3000 | $281.90 | 83,283.0000 | 190,311,000 | 3.48% | 0.00% |
| Aug. 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 2000 | $0.00 | 6,000.0000 | 190,311,000 | 25.00% | 0.00% |
| Aug. 1, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 50 | $281.90 | 8,486.0000 | 190,311,000 | 0.59% | 0.00% |
| July 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 32,038.0000 | 190,311,000 | 20.00% | 0.00% |
| July 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $256.72 | 455,503.0000 | 190,311,000 | 1.73% | 0.00% |
| July 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 463,512.0000 | 190,311,000 | 1.76% | 0.00% |
| July 2, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 945 | $255.49 | 68,273.0000 | 190,311,000 | 1.37% | 0.00% |
| July 1, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 3883 | $256.99 | 84,283.0000 | 190,311,000 | 4.40% | 0.00% |
| July 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 1966 | $0.00 | 8,917.0000 | 190,311,000 | 18.06% | 0.00% |
| July 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 917 | $0.00 | 8,000.0000 | 190,311,000 | 10.28% | 0.00% |
| July 1, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 66 | $256.99 | 8,536.0000 | 190,311,000 | 0.77% | 0.00% |
| July 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 917 | $101.64 | 88,166.0000 | 190,311,000 | 1.05% | 0.00% |
| July 1, 2025 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 1966 | $101.64 | 87,249.0000 | 190,311,000 | 2.31% | 0.00% |
| June 9, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 40,047.0000 | 190,049,000 | 16.67% | 0.00% |
| June 9, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 465,602.0000 | 190,049,000 | 1.75% | 0.00% |
| June 9, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $251.21 | 457,593.0000 | 190,049,000 | 1.72% | 0.00% |
| June 4, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $247.32 | 69,218.0000 | 190,049,000 | 2.81% | 0.00% |
| June 2, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 41 | $243.78 | 8,870.0000 | 190,049,000 | 0.46% | 0.00% |
| June 2, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $243.78 | 85,283.0000 | 190,049,000 | 1.16% | 0.00% |
| June 2, 2025 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 267 | $244.79 | 8,603.0000 | 190,049,000 | 3.01% | 0.00% |
| May 22, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 3644 | $244.59 | 86,283.0000 | 190,049,000 | 4.05% | 0.00% |
| May 20, 2025 | De Witte Jan | Director | S | ReMed Common Stock | 2000 | $243.47 | 5,806.0000 | 190,049,000 | 25.62% | 0.00% |
| May 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 465,602.0000 | 190,049,000 | 1.75% | 0.00% |
| May 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $243.23 | 457,593.0000 | 190,049,000 | 1.72% | 0.00% |
| May 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 48,056.0000 | 190,049,000 | 14.29% | 0.00% |
| May 7, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $242.25 | 71,218.0000 | 190,049,000 | 2.73% | 0.00% |
| April 8, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $215.58 | 89,864.0000 | 190,049,000 | 1.10% | 0.00% |
| April 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 465,572.0000 | 190,049,000 | 1.75% | 0.00% |
| April 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $209.85 | 457,562.0000 | 190,049,000 | 1.72% | 0.00% |
| April 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 56,065.0000 | 190,049,000 | 12.50% | 0.00% |
| April 2, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $219.74 | 73,218.0000 | 190,049,000 | 2.66% | 0.00% |
| April 1, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 64 | $222.86 | 8,846.0000 | 190,049,000 | 0.72% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 169 | $0.00 | 0.0000 | 190,049,000 | 100.00% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 105 | $0.00 | 0.0000 | 190,049,000 | 100.00% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 5882 | $0.00 | 0.0000 | 190,049,000 | 100.00% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 3589 | $0.00 | 0.0000 | 190,049,000 | 100.00% | 0.00% |
| March 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 465,571.0000 | 190,049,000 | 1.75% | 0.00% |
| March 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $229.20 | 457,562.0000 | 190,049,000 | 1.72% | 0.00% |
| March 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 64,074.0000 | 190,049,000 | 11.11% | 0.00% |
| March 10, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $230.36 | 90,864.0000 | 190,049,000 | 1.09% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 169 | $146.34 | 9,894.0000 | 190,049,000 | 1.74% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 105 | $211.76 | 9,999.0000 | 190,049,000 | 1.06% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 3589 | $146.34 | 13,588.0000 | 190,049,000 | 35.89% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 5882 | $211.76 | 19,470.0000 | 190,049,000 | 43.29% | 0.00% |
| March 10, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 9745 | $239.31 | 9,725.0000 | 190,049,000 | 50.05% | 0.01% |
| March 5, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $227.71 | 75,218.0000 | 190,049,000 | 2.59% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 514 | $146.34 | 14,112.0000 | 190,049,000 | 3.78% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 367 | $211.76 | 10,092.0000 | 190,049,000 | 3.77% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 3506 | $146.34 | 13,598.0000 | 190,049,000 | 34.74% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 4726 | $211.76 | 18,838.0000 | 190,049,000 | 33.49% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 367 | $235.25 | 18,471.0000 | 190,049,000 | 1.95% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 3506 | $235.40 | 14,965.0000 | 190,049,000 | 18.98% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 514 | $235.25 | 14,451.0000 | 190,049,000 | 3.43% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 4726 | $235.43 | 9,725.0000 | 190,049,000 | 32.70% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 367 | $0.00 | 105.0000 | 190,049,000 | 77.75% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 3506 | $0.00 | 3,589.0000 | 190,049,000 | 49.42% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 514 | $0.00 | 169.0000 | 190,049,000 | 75.26% | 0.00% |
| March 3, 2025 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 4726 | $0.00 | 5,882.0000 | 190,049,000 | 44.55% | 0.00% |
| March 3, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 64 | $234.10 | 8,910.0000 | 190,049,000 | 0.71% | 0.00% |
| Feb. 7, 2025 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 8009 | $236.77 | 457,562.0000 | 190,049,000 | 1.72% | 0.00% |
| Feb. 10, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $238.98 | 91,864.0000 | 190,049,000 | 1.08% | 0.00% |
| Feb. 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 8009 | $101.64 | 465,571.0000 | 190,049,000 | 1.75% | 0.00% |
| Feb. 7, 2025 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 8009 | $0.00 | 72,083.0000 | 190,049,000 | 10.00% | 0.00% |
| Feb. 5, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $242.11 | 77,218.0000 | 190,049,000 | 2.52% | 0.00% |
| Feb. 3, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 64 | $242.42 | 8,974.0000 | 190,049,000 | 0.71% | 0.00% |
| Jan. 8, 2025 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $234.04 | 92,864.0000 | 190,049,000 | 1.07% | 0.00% |
| Jan. 2, 2025 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $230.99 | 79,218.0000 | 190,049,000 | 2.46% | 0.00% |
| Jan. 2, 2025 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 75 | $230.99 | 9,038.0000 | 190,049,000 | 0.82% | 0.00% |
| Dec. 9, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $244.23 | 93,864.0000 | 189,662,000 | 1.05% | 0.00% |
| Dec. 4, 2024 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $245.65 | 81,218.0000 | 189,662,000 | 2.40% | 0.00% |
| Nov. 29, 2024 | Rider Michael J | Global General Counsel | G | ResMed Common Stock | 173 | $0.00 | 9,187.0000 | 189,662,000 | 1.85% | 0.00% |
| Dec. 2, 2024 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 74 | $248.91 | 9,113.0000 | 189,662,000 | 0.81% | 0.00% |
| Nov. 27, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 2000 | $249.67 | 457,562.0000 | 189,662,000 | 0.44% | 0.00% |
| Nov. 27, 2024 | Farrell Michael J. | Chief Executive Officer | G | ResMed Common Stock | 2000 | $0.00 | 457,562.0000 | 189,662,000 | 0.44% | 0.00% |
| Nov. 27, 2024 | Farrell Michael J. | Chief Executive Officer | G | ResMed Common Stock | 2000 | $0.00 | 459,562.0000 | 189,662,000 | 0.44% | 0.00% |
| Nov. 25, 2024 | Farrell Michael J. | Chief Executive Officer | A | ResMed Common Stock Options | 33036 | $249.56 | 33,036.0000 | 189,662,000 | 9999.99% | 0.02% |
| Nov. 25, 2024 | FARRELL PETER C | Director | A | ResMed Common Stock Options | 1468 | $249.56 | 1,468.0000 | 189,662,000 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Leong Justin | Chief Product Officer | S | ReMed Common Stock | 6160 | $243.09 | 21,718.0000 | 189,662,000 | 22.10% | 0.00% |
| Nov. 20, 2024 | Burt Carol | Director | A | ResMed Common Stock | 1083 | $0.00 | 2,851.0000 | 189,662,000 | 61.26% | 0.00% |
| Nov. 20, 2024 | FARRELL PETER C | Director | A | ResMed Common Stock | 542 | $0.00 | 83,218.0000 | 189,662,000 | 0.66% | 0.00% |
| Nov. 20, 2024 | TAYLOR RONALD R | Director | A | ResMed Common Stock | 1083 | $0.00 | 23,698.0000 | 189,662,000 | 4.79% | 0.00% |
| Nov. 20, 2024 | Tan Desney | Director | A | ResMed Common Stock | 1083 | $0.00 | 4,929.0000 | 189,662,000 | 28.16% | 0.00% |
| Nov. 20, 2024 | SULPIZIO RICHARD | Director | A | ResMed Common Stock | 1083 | $0.00 | 17,796.0000 | 189,662,000 | 6.48% | 0.00% |
| Nov. 20, 2024 | Drexler Karen | Director | A | ResMed Common Stock | 1083 | $0.00 | 9,529.0000 | 189,662,000 | 12.82% | 0.00% |
| Nov. 20, 2024 | De Witte Jan | Director | A | ReMed Common Stock | 1083 | $0.00 | 7,806.0000 | 189,662,000 | 16.11% | 0.00% |
| Nov. 20, 2024 | Hernandez John | Director | A | ResMed Common Stock | 1083 | $0.00 | 4,045.0000 | 189,662,000 | 36.56% | 0.00% |
| Nov. 20, 2024 | Gill Harjit | Director | A | ResMed Common Stock | 1083 | $0.00 | 9,905.0000 | 189,662,000 | 12.28% | 0.00% |
| Nov. 20, 2024 | DelOrefice Christopher | Director | A | ResMed Common Stock | 1083 | $0.00 | 1,350.0000 | 189,662,000 | 405.62% | 0.00% |
| Nov. 12, 2024 | De Witte Jan | Director | S | ReMed Common Stock | 796 | $248.81 | 6,723.0000 | 189,662,000 | 10.59% | 0.00% |
| Nov. 11, 2024 | Farrell Michael J. | Chief Executive Officer | F | ResMed Common Stock | 3453 | $252.38 | 459,562.0000 | 189,662,000 | 0.75% | 0.00% |
| Nov. 8, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $249.00 | 94,864.0000 | 189,662,000 | 1.04% | 0.00% |
| Nov. 11, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | F | ResMed Common Stock | 1418 | $252.38 | 9,725.0000 | 189,662,000 | 12.72% | 0.00% |
| Nov. 11, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | F | ResMed Common Stock | 446 | $252.38 | 11,142.0000 | 189,662,000 | 3.85% | 0.00% |
| Nov. 11, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | F | ResMed Common Stock | 603 | $252.38 | 11,588.0000 | 189,662,000 | 4.95% | 0.00% |
| Nov. 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 14683 | $0.00 | 0.0000 | 189,662,000 | 100.00% | 0.01% |
| Nov. 11, 2024 | Farrell Michael J. | Chief Executive Officer | F | ResMed Common Stock | 2227 | $252.38 | 463,015.0000 | 189,662,000 | 0.48% | 0.00% |
| Nov. 11, 2024 | Farrell Michael J. | Chief Executive Officer | F | ResMed Common Stock | 3101 | $252.38 | 465,242.0000 | 189,662,000 | 0.66% | 0.00% |
| Nov. 7, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $246.26 | 468,344.0000 | 189,662,000 | 3.04% | 0.01% |
| Nov. 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 14683 | $84.98 | 483,027.0000 | 189,662,000 | 3.14% | 0.01% |
| Nov. 11, 2024 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 137 | $252.38 | 9,360.0000 | 189,662,000 | 1.44% | 0.00% |
| Nov. 11, 2024 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 172 | $252.38 | 9,497.0000 | 189,662,000 | 1.78% | 0.00% |
| Nov. 11, 2024 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 134 | $252.38 | 9,669.0000 | 189,662,000 | 1.37% | 0.00% |
| Nov. 11, 2024 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 685 | $252.38 | 9,803.0000 | 189,662,000 | 6.53% | 0.00% |
| Nov. 11, 2024 | Gill Harjit | Director | F | ResMed Common Stock | 133 | $252.38 | 8,822.0000 | 189,662,000 | 1.48% | 0.00% |
| Nov. 11, 2024 | FARRELL PETER C | Director | F | ResMed Common Stock | 528 | $252.38 | 82,676.0000 | 189,662,000 | 0.63% | 0.00% |
| Nov. 6, 2024 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $248.74 | 83,204.0000 | 189,662,000 | 2.35% | 0.00% |
| Nov. 1, 2024 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 69 | $242.00 | 10,443.0000 | 189,662,000 | 0.66% | 0.00% |
| Oct. 30, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | J | ResMed Common Stock | 9628 | $0.00 | 12,160.0000 | 189,662,000 | 44.19% | 0.01% |
| Oct. 30, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | J | ResMed Common Stock | 9628 | $0.00 | 9,628.0000 | 189,662,000 | 0.00% | 0.01% |
| Oct. 11, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 4260 | $238.48 | 21,788.0000 | 189,662,000 | 16.35% | 0.00% |
| Oct. 11, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 4260 | $0.00 | 0.0000 | 189,662,000 | 100.00% | 0.00% |
| Oct. 11, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 4260 | $101.64 | 26,048.0000 | 189,662,000 | 19.55% | 0.00% |
| Oct. 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 14683 | $84.98 | 482,942.0000 | 189,662,000 | 3.14% | 0.01% |
| Oct. 8, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $233.47 | 95,812.0000 | 189,662,000 | 1.03% | 0.00% |
| Oct. 7, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $231.91 | 468,259.0000 | 189,662,000 | 3.04% | 0.01% |
| Oct. 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 14683 | $0.00 | 14,683.0000 | 189,662,000 | 50.00% | 0.01% |
| Oct. 2, 2024 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $237.20 | 85,204.0000 | 189,662,000 | 2.29% | 0.00% |
| Sept. 12, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock | 5000 | $101.64 | 26,788.0000 | 189,565,000 | 22.95% | 0.00% |
| Sept. 12, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | S | ResMed Common Stock | 5000 | $252.56 | 21,788.0000 | 189,565,000 | 18.67% | 0.00% |
| Sept. 12, 2024 | Ghoshal Kaushik | Chief Commercial Officer, SaaS | M | ResMed Common Stock Options | 5000 | $0.00 | 4,260.0000 | 189,565,000 | 54.00% | 0.00% |
| Sept. 9, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 14683 | $84.98 | 482,942.0000 | 189,565,000 | 3.14% | 0.01% |
| Sept. 9, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $246.42 | 96,812.0000 | 189,565,000 | 1.02% | 0.00% |
| Sept. 9, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $248.38 | 468,259.0000 | 189,565,000 | 3.04% | 0.01% |
| Sept. 9, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 14683 | $0.00 | 29,366.0000 | 189,565,000 | 33.33% | 0.01% |
| Sept. 4, 2024 | FARRELL PETER C | Director | S | ResMed Common Stock | 2000 | $239.90 | 87,204.0000 | 189,565,000 | 2.24% | 0.00% |
| Sept. 3, 2024 | DelOrefice Christopher | Director | A | ResMed Common Stock | 267 | $0.00 | 267.0000 | 189,565,000 | 9999.99% | 0.00% |
| Aug. 20, 2024 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 882 | $231.00 | 10,512.0000 | 189,565,000 | 7.74% | 0.00% |
| Aug. 15, 2024 | Sandercock Brett | Chief Financial Officer | A | ResMed Common Stock | 7915 | $0.00 | 96,971.0000 | 189,565,000 | 8.89% | 0.00% |
| Aug. 15, 2024 | Sandercock Brett | Chief Financial Officer | A | ResMed Common Stock | 841 | $0.00 | 97,812.0000 | 189,565,000 | 0.87% | 0.00% |
| Aug. 15, 2024 | Rider Michael J | Global General Counsel | A | ResMed Common Stock | 4474 | $0.00 | 10,918.0000 | 189,565,000 | 69.43% | 0.00% |
| Aug. 15, 2024 | Rider Michael J | Global General Counsel | A | ResMed Common Stock | 476 | $0.00 | 11,394.0000 | 189,565,000 | 4.36% | 0.00% |
| Aug. 15, 2024 | Leong Justin | Chief Product Officer | A | ReMed Common Stock | 8259 | $0.00 | 27,000.0000 | 189,565,000 | 44.07% | 0.00% |
| Aug. 15, 2024 | Leong Justin | Chief Product Officer | A | ReMed Common Stock | 878 | $0.00 | 27,878.0000 | 189,565,000 | 3.25% | 0.00% |
| Aug. 15, 2024 | Ghoshal Kaushik | President, SaaS Business | A | ResMed Common Stock | 7915 | $0.00 | 20,947.0000 | 189,565,000 | 60.74% | 0.00% |
| Aug. 15, 2024 | Ghoshal Kaushik | President, SaaS Business | A | ResMed Common Stock | 841 | $0.00 | 21,788.0000 | 189,565,000 | 4.01% | 0.00% |
| Aug. 15, 2024 | Farrell Michael J. | Chief Executive Officer | A | ResMed Common Stock | 19272 | $0.00 | 464,161.0000 | 189,565,000 | 4.33% | 0.01% |
| Aug. 15, 2024 | Farrell Michael J. | Chief Executive Officer | A | ResMed Common Stock | 4098 | $0.00 | 468,259.0000 | 189,565,000 | 0.88% | 0.00% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | S | ResMed Common Stock | 10000 | $216.60 | 13,032.0000 | 189,565,000 | 43.42% | 0.01% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | M | ResMed Common Stock Options | 1037 | $0.00 | 9,260.0000 | 189,565,000 | 10.07% | 0.00% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | M | ResMed Common Stock Options | 6877 | $0.00 | 0.0000 | 189,565,000 | 100.00% | 0.00% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | M | ResMed Common Stock Options | 2086 | $0.00 | 0.0000 | 189,565,000 | 100.00% | 0.00% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | M | ResMed Common Stock | 1037 | $101.64 | 23,032.0000 | 189,565,000 | 4.71% | 0.00% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | M | ResMed Common Stock | 6877 | $95.80 | 21,995.0000 | 189,565,000 | 45.49% | 0.00% |
| Aug. 12, 2024 | Ghoshal Kaushik | President, SaaS Business | M | ResMed Common Stock | 2086 | $95.80 | 15,118.0000 | 189,565,000 | 16.01% | 0.00% |
| Aug. 8, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $212.16 | 89,056.0000 | 189,565,000 | 1.11% | 0.00% |
| Aug. 7, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $214.25 | 444,889.0000 | 189,565,000 | 3.19% | 0.01% |
| Aug. 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 14683 | $0.00 | 44,049.0000 | 189,565,000 | 25.00% | 0.01% |
| Aug. 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 14683 | $84.98 | 459,572.0000 | 189,565,000 | 3.30% | 0.01% |
| Aug. 5, 2024 | Leong Justin | President, Asia Latin America | S | ReMed Common Stock | 48000 | $217.07 | 18,741.0000 | 189,565,000 | 71.92% | 0.03% |
| July 8, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 14683 | $84.98 | 459,572.0000 | 189,565,000 | 3.30% | 0.01% |
| July 8, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $192.97 | 444,889.0000 | 189,565,000 | 3.19% | 0.01% |
| July 8, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 14683 | $0.00 | 58,732.0000 | 189,565,000 | 20.00% | 0.01% |
| July 8, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $194.35 | 90,056.0000 | 189,565,000 | 1.10% | 0.00% |
| June 10, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 1000 | $209.81 | 91,056.0000 | 188,901,000 | 1.09% | 0.00% |
| June 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 14683 | $84.98 | 459,572.0000 | 188,901,000 | 3.30% | 0.01% |
| June 7, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $211.66 | 444,889.0000 | 188,901,000 | 3.19% | 0.01% |
| June 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 14683 | $0.00 | 73,415.0000 | 188,901,000 | 16.67% | 0.01% |
| June 4, 2024 | Rider Michael J | Global General Counsel | F | ResMed Common Stock | 267 | $206.33 | 6,444.0000 | 188,901,000 | 3.98% | 0.00% |
| May 24, 2024 | Burt Carol | Director | G | ResMed Common Stock | 47 | $0.00 | 14,892.0000 | 188,901,000 | 0.31% | 0.00% |
| May 15, 2024 | De Witte Jan | Director | S | ReMed Common Stock | 360 | $218.29 | 7,519.0000 | 188,901,000 | 4.57% | 0.00% |
| May 15, 2024 | De Witte Jan | Director | S | ReMed Common Stock | 360 | $218.29 | 7,519.0000 | 188,901,000 | 4.57% | 0.00% |
| May 15, 2024 | FARRELL PETER C | Director | G | ResMed Common Stock | 68200 | $0.00 | 89,204.0000 | 188,901,000 | 43.33% | 0.04% |
| May 8, 2024 | Sandercock Brett | Chief Financial Officer | S | ResMed Common Stock | 13000 | $211.37 | 92,056.0000 | 188,901,000 | 12.37% | 0.01% |
| May 8, 2024 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock | 12000 | $101.64 | 105,056.0000 | 188,901,000 | 12.90% | 0.01% |
| May 8, 2024 | Sandercock Brett | Chief Financial Officer | M | ResMed Common Stock Options | 12000 | $0.00 | 10,883.0000 | 188,901,000 | 52.44% | 0.01% |
| May 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 13507 | $84.98 | 459,525.0000 | 188,901,000 | 3.03% | 0.01% |
| May 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock | 1176 | $84.98 | 446,018.0000 | 188,901,000 | 0.26% | 0.00% |
| May 7, 2024 | Farrell Michael J. | Chief Executive Officer | S | ResMed Common Stock | 14683 | $216.50 | 444,842.0000 | 188,901,000 | 3.20% | 0.01% |
| May 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 1176 | $0.00 | 101,605.0000 | 188,901,000 | 1.14% | 0.00% |
| May 7, 2024 | Farrell Michael J. | Chief Executive Officer | M | ResMed Common Stock Options | 13507 | $0.00 | 88,098.0000 | 188,901,000 | 13.29% | 0.01% |
| April 29, 2024 | Burt Carol | Director | G | ResMed Common Stock | 234 | $0.00 | 14,939.0000 | 188,901,000 | 1.54% | 0.00% |
| April 29, 2024 | Drexler Karen | Director | S | ResMed Common Stock | 425 | $214.92 | 8,446.0000 | 188,901,000 | 4.79% | 0.00% |
| March 4, 2024 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 81 | $180.00 | 6,607.0000 | 188,901,000 | 1.21% | 0.00% |
| March 1, 2024 | Rider Michael J | Global General Counsel | S | ResMed Common Stock | 200 | $173.25 | 6,688.0000 | 188,901,000 | 2.90% | 0.00% |
| Feb. 22, 2024 | FARRELL PETER C | Director | S | ResMed Common Stock | 10935 | $182.66 | 157,404.0000 | 188,901,000 | 6.50% | 0.01% |
| May 3, 2023 | FARRELL PETER C | Director | S | ResMed Common Stock | 12600 | $237.17 | 166,896.0000 | 188,247,000 | 7.02% | 0.01% |